Restricted accessBrief reportFirst published online 2014-08
Evaluation of Multiple-Turnover Capability of Locked Nucleic Acid Antisense Oligonucleotides in Cell-Free RNase H-Mediated Antisense Reaction and in Mice
The multiple-turnover ability of a series of locked nucleic acid (LNA)-based antisense oligonucleotides (AONs) in the RNase H-mediated scission reaction was estimated using a newly developed cell-free reaction system. We determined the initial reaction rates of AONs under multiple-turnover conditions and found that among 24 AONs tested, AONs with melting temperatures (Tm) of 40°C–60°C efficiently elicit multiple rounds of RNA scission. On the other hand, by measuring Tm with two 10-mer RNAs partially complementary to AONs as models of cleaved 5′ and 3′ fragments of mRNA, we found that AONs require adequate binding affinity for efficient turnover activities. We further demonstrated that the efficacy of a set of 13-mer AONs in mice correlated with their turnover efficiency, indicating that the intracellular situation where AONs function is similar to multiple-turnover conditions. Our methodology and findings may provide an opportunity to shed light on a previously unknown antisense mechanism, leading to further improvement of the activity and safety profiles of AONs.
Get full access to this article
View all access options for this article.
References
1.
CROOKES.T., LEMONIDISK.M., NEILSONL., GRIFFEYR., LESNIKE.A., and MONIAB.P. (1995). Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J., 312, 599–608.
2.
CROOKET.S. (2007). Antisense Drug Technologies: Principles, Strategies, and Applications. 2nd ed. (CRC Press Taylor & Francis Group, Boca Raton, FL).
3.
GAOW.Y., HANF.S., STORMC., EGANW., and CHENGY.C. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol., 41, 223–229.
4.
HARIY., OBIKAS., OHNISHIR., EGUCHIK., OSAKIT., OHISHIH., and IMANISHIT. (2006). Synthesis and properties of 2′-O,4-C-methyleneoxymethylene bridged nucleic acid. Bioorgan. Med. Chem., 14, 1029–1038.
5.
HUTVAGNERG., and ZAMOREP.D. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science, 297, 2056–2060.
6.
KOLLERE., VINCENTT. M., CHAPPELLA., DES., MANOHARANM., and BENNETTC. F. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795–4807.
7.
KURRECKJ., WYSZKOE., GILLENC., and ERDMANNV.A. (2002). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911–1918.
8.
LIMAW.F., and CROOKES.T. (1997). Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry, 36, 390–398.
9.
LIMAW.F., ROSEJ.B., NICHOLSJ.G., WUH.J., MIGAWAM.T., WYRZYKIEWICZT.K., SIWKOWSKIA.M., and CROOKES.T. (2007a). Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol., 71, 83–91.
10.
LIMAW.F., ROSEJ.B., NICHOLSJ.G., WUH.J., MIGAWAM.T., WYRZYKIEWICZT.K., VASQUEZG., SWAYZEE.E., and CROOKES.T. (2007b). The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol. Pharmacol., 71, 73–82.
11.
MIYASHITAK., RAHMANS.M.A., SEKIS., OBIKAS., and IMANISHIT. (2007). N-Methyl substituted 2 ′,4 ′-BNANC: a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization. Chem. Commun., 2007, 3765–3767.
12.
MONIAB.P., LESNIKE.A., GONZALEZC., LIMAW.F., MCGEED., GUINOSSOC.J., KAWASAKIA.M., COOKP.D., and FREIERS.M. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514–14522.
13.
NOWOTNYM., GAIDAMAKOVS.A., GHIRLANDOR., CERRITELLIS.M., CROUCHR.J., and YANGW. (2007). Structure of human RNase h1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell, 28, 264–276.
14.
OBIKAS., NANBUD., HARIY., ANDOHJ., MORIOK., DOIT., and IMANISHIT. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett., 39, 5401–5404.
15.
OBIKAS., NANBUD., HARIY., MORIOK., INY., ISHIDAT., and IMANISHIT. (1997). Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C-3,-endo sugar puckering. Tetrahedron Lett., 38, 8735–8738.
16.
PRAKASHT.P., SIWKOWSKIA., ALLERSONC.R., MIGAWAM.T., LEES., GAUSH.J., BLACKC., SETHP.P., SWAYZEE.E., and BHATB. (2010). Antisense oligonucleotides containing conformationally constrained 2′,4′-(N-methoxy)aminomethylene and 2′,4′-aminooxymethylene and 2′-O,4′-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J. Med. Chem., 53, 1636–1650.
17.
SETHP.P., SIWKOWSKIA., ALLERSONC.R., VASQUEZG., LEES., PRAKASHT.P., WANCEWICZE.V., WITCHELLD., and SWAYZEE.E. (2009). Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10–13.
18.
SINGHS.K., NIELSENP., KOSHKINA.A., and WENGELJ. (1998). LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem. Commun., 1998, 455–456.
19.
SOHLENIUS-STERNBECKA.K. (2006) Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol. In Vitro 20, 1582–1586.
20.
STANTONR., SCIABOLAS., SALATTOC., WENGY., MOSHINSKYD., LITTLEJ., WALTERSE., KREEGERJ., et al. (2012). Chemical modification study of antisense gapmers. Nucleic Acid Ther., 22, 344–359.
21.
STEINC.A., HANSENJ.B., LAIJ., WUS., VOSKRESENSKIYA., HOGA., WORMJ., HEDTJARNM., SOULEIMANIANN., MILLERP., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38, e3.
22.
STRAARUPE.M., FISKERN., HEDTJARNM., LINDHOLMM.W., ROSENBOHMC., AARUPV., HANSENH.F., ORUMH., HANSENJ.B., and KOCHT. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res., 38, 7100–7111.
23.
VESTERB., BOELA.M., LOBEDANZS., BABUB.R., RAUNKJAERM., LINDEGAARDD., RAUNAKHR, DLICKAP.J., HOJLANDT., et al. (2008). Chemically modified oligonucleotides with efficient RNase H response. Bioorg. Med. Chem. Lett., 18, 2296–2300.
24.
WATANABET.A., GEARYR.S., and LEVINA.A. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16, 169–180.
25.
YAHARAA., SHRESTHAA.R., YAMAMOTOT., HARIY., OSAWAT., YAMAGUCHIM., NISHIDAM., KODAMAT., and OBIKAS. (2012). Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency. Chembiochem, 13, 2513–2516.
YAMAMOTOT., NAKATANIM., NARUKAWAK., and OBIKAS. (2011). Antisense drug discovery and development. Future Med. Chem., 3, 339–365.
28.
YAMAMOTOT., YASUHARAH., WADAF., HARADA-SHIBAM., IMANISHIT., and OBIKAS. (2012b). Superior silencing by 22,42-BNANC-Based short antisense oligonucleotides compared to 22,42-BNA/LNA-based apolipoprotein B antisense inhibitors. J. Nucleic Acids, Article ID. 707323.
29.
ZHANGY., QUZ., KIMS., SHIV., LIAOB., KRAFTP., BANDARUR., WUY., GREENBERGERL.M., and HORAKI.D. (2011). Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther, 18, 326–333.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
